Accepted Manuscript

Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-Lactones)

Jihyae Ann , Suyoung Yoon , Jisoo Baek , Da Hye Kim , Nancy E. Lewin , Colin S. Hill , Peter M. Blumberg , Jeewoo Lee

Please cite this article as: J. Ann, S. Yoon, J. Baek, D.H. Kim, N.E. Lewin, C.S. Hill, P.M. Blumberg, J. Lee, Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-Lactones), *European Journal of Medicinal Chemistry* (2014), doi: 10.1016/j.ejmech.2014.11.025.

Graphical Abstract

DAG-lactone

104

K_i ratio (PKCα/PKCϵ)

100% phosphatidylserine : 8
nuclear membrane lipid : 32

Design and Synthesis of Protein Kinase C Epsilon Selective Diacylglycerol Lactones (DAG-Lactones)

Jihyae Ann [a], Suyoung Yoon [a], Jisoo Baek [a], Da Hye Kim [a], Nancy E. Lewin [b], Colin S. Hill [b], Peter M. Blumberg [b], Jeewoo Lee [a,*]

[a] Laboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 151-742, Korea

[b] Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA

To whom correspondence should be addressed.
Phone: 82-2-880-7846
Fax: 82-2-888-0649
E-mail: *jeewoo@snu.ac.kr*

1

Abstract

DAG-lactones afford a synthetically accessible, high affinity platform for probing structure activity relationships at the C1 regulatory domain of protein kinase C (PKC). Given the central role of PKC isoforms in cellular signaling, along with their differential biological activities, a critical objective is the design of isoform selective ligands. Here, we report the synthesis of a series of DAG-lactones varying in their side chains, with a particular focus on linoleic acid derivatives. We evaluated their selectivity for PKC epsilon versus PKC alpha both under standard lipid conditions (100% phosphatidylserine, PS) as well as in the presence of a nuclear membrane mimetic lipid mixture (NML). We find that selectivity for PKC epsilon versus PKC alpha tended to be enhanced in the presence of the nuclear membrane mimetic lipid mixture and, for our lead compound, report a selectivity of 32-fold.

1. Introduction

Protein kinase Cs (PKCs) represent a family of serine/threonine kinases which are central signaling elements downstream of the numerous cellular receptors that are coupled to phospholipase C activation [1]. PKCs display complex regulation, with membrane phospholipids and diacylglycerol being critical regulators and elevated Ca^{2+} additionally being important for the classical PKCs. PKC isoforms divide into three groups; classical PKCs (cPKCs: PKCα, PKCβI, PKCβII and PKCγ), novel PKCs (nPKCs: PKCδ, PKCε, PKCη and PKCθ) and atypical PKCs (aPKCs: PKCξ, PKCι/λ), distinguished by their Ca^{2+} dependency and cofactors for activation [2,3]. Additionally, individual isozymes vary in their patterns of tissue distribution, subcellular localization, substrate specificity, and biological function [4,5]. For example, different isoforms may be growth promoting or growth inhibitory, with stimulation of one isoform being functionally antagonistic of another [6]. Although the high level of conservation of the regulatory domains of PKC isoforms poses a challenge for the development of isoform selective ligands, the complexity of their regulation also provides promising opportunities [7].

Among the PKC isozymes, particular attention has focused on protein kinase C epsilon (PKC-ε), one of the calcium-independent but phorbol ester/ diacylglycerol dependent novel PKC isoforms. Structurally, it contains an N-terminal regulatory domain and C-terminal kinase domain composed on four conserved (C1-C4) and five variable (V1-V5) regions. The regulatory domain contains a pseudosubstrate domain which inhibits PKC activity before activation, a tandem repeat of C1 domain zinc finger structures that bind diacylglycerol (DAG) and phorbol ester, and a C2-like domain which contributes to membrane interaction [8,9]. Additionally, PKC-ε possesses a unique actin-binding site [10] between the first and second cysteine rich C1-domains which promotes association with actin filaments in intact cells. Due to its specific tissue distribution and localization pattern, it has been reported that PKC-ε has critical roles in both the cardiovascular and central nervous system [11] such as cardioprotection [12], neurite outgrowth [13], synapse formation, neurotransmitter release, synaptic loss prevention [14], and sensitization to

3

1 pain through TRPV1 [15].

2   As an initial effort to design and develop PKC-ε selective ligands, our attention was

3 drawn to reports that saturated and unsaturated fatty acids may influence PKC-ε activity. Recent-

4 ly, Nishizaki and co-workers described that a linoleic acid derivative with cyclopropane rings

5 replacing the cis-double bonds, *viz.* 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic

6 acid (DCP-LA, Figure 2. Compound **5**) acted as a selective and direct activator of PKC-ε [16]. In

7 biological studies, DCP-LA effectively prevented both deposition of amyloid plaques and loss of

8 synaptic connections [17].

9   Previously, we have demonstrated that diacylglycerol lactones (DAG-lactones), which

10 are rigidified structures derived from the endogenous PKC ligand DAG, function as DAG ana-

11 logs to potently bind to the regulatory C1 domain of PKC and cause PKC activation [18]. For

12 this binding, both the acyl (R_1) and α-alkylidene (R_2) positions are critical elements in control-

13 ling biological activity and PKC isozyme selectivity [19]. Modeling reveals that there are two

14 different modes of binding, involving interaction between the C1 domain and either the *sn*-1 car-

15 bonyl or the *sn*-2 carbonyl. The alkyl chain which is not involved in hydrogen bonding to the

16 binding cleft of the C1 domain contributes to the binding energy through its interactions with the

17 C1 domain surface and the lipid bilayer.

18   In this study, we have evaluated whether the incorporation of linoleic and DCP-LA deriv-

19 atives into the side chains of DAG-lactones would provide combined structures with enhanced

20 selectivity for PKCε. The newly designed linoleic acid derivatives, incorporating cyclo-saturated

21 (**2**, **5**), linear-unsaturated (**10**, **12**), linear-saturated (**11**), and branched alkyl chains (**13**-**15**), were

22 alternatively attached to the carbonyl group for acyl branching (R_1) or connected to the lactone

23 via a methylene group for α-alkylidene branching (R_2). Novel features of the study include both

24 the specific class of DAG-lactones themselves as well as their analysis, directed at comparing

25 selectivities for the novel PKCε isoform relative to that for the classical PKCα isoform.

26

2. Result and discussion

2.1. Chemistry

As illustrated in Figure 2, three branched groups as well as linoleic acid and five different linoleic acid derivatives in which the *cis*-double bonds were replaced by other groups were introduced as R_1 and R_2 side chains. Commercially available linoleic acid (**1**), stearic acid (**11**), octadec-9-ynoic acid (**12**), and the branched compounds pivaloyl chloride (**13**) and isovaleraldehyde (**15**) were directly used for alkylation. Among the branched-substituents, 3-isobutyl-5-methylhexanoyl chloride (**14**) [20] and 3-isobutyl-5-methylhexanal (**16**) [21] were prepared according to previously published methods.

Starting from linoleic acid **1**, cyclo-saturated acid derivatives were synthesized. Di-epoxy compound (DEP-LA, **2**) was achieved by the conventional *m*CPBA epoxidation (Scheme 1). Simmons-smith cyclopropanation [22] of methyl (9Z, 12Z)-octadeca-9,12-dienoate (**3**) followed by hydrolysis of the ester gave the di-cyclopropane compound (DCP-LA, **5**). The diyne core of compound **10** was assembled by a Cadiot-Chodkiewicz coupling [23] between bromoalkyne **7** and a suitably acid functionalized terminal alkyne **9** (Scheme 2). As illustrated in scheme 3, the aldehydes **20**-**22** were generated from the alcohols **17**-**19**, which were derived from the corresponding esters (**3**, **4**) and acid (**11**), by treatment with the Dess-Martin periodinane.

Scheme 1. Synthesis of cyclo-saturated alkyl acids.

Reagents and Conditions: (a) mCPBA, CH_2Cl_2, 0°C; (b) $SOCl_2$, CH_3OH, r.t.; (c) Et_2Zn,CH_2I_2,CH_2Cl_2, -5°C; (d) 1N LiOH, dioxane, 60°C.

Scheme 2. Synthesis of the unsaturated-diyne derivative.

Reagents and Conditions: (a) NBS, $AgNO_3$, Acetone, r.t.; (b) CrO_3, H_2SO_4, H_2O, Acetone, -5°C; (c) CuCl, 30% n-BuNH$_2$, NH$_2$OHHCl, Et_2O, r.t.

Scheme 3. Synthesis of aldehydes for *sn*-2 alkylation

Reagents and Conditions: (a) LAH, Et_2O, reflux; (b) $(COCl)_2$, DMSO, Et_3N, CH_2Cl_2, -78°C; (c) DMP, CH_2Cl_2, 0°C.

Depending on the specific substituents, different protecting groups were selected (**Table 1**). Specially, the TBDPS group was used for the synthesis of DEP-LA (**90, 91**) due to its sensitivity to the deprotection conditions with BCl$_3$ and CAN.

1
2
3
4 **Scheme 4.** General scheme for alkylation.
5 Reagents and Conditions: (a) i) LiHMDS, THF, R_2CHO, -78°C. ii) MsCl, CH_2Cl_2, DBU; (b) BCl_3,
6 CH_2Cl_2, -78°C or CAN, CH_3CN/H_2O; (c) TBAF, THF; (d) EDC, DMAP, CH_2Cl_2, r.t.; (e)
7 TEA, DMAP, CH_2Cl_2, r.t.; (f) BCl_3, CH_2Cl_2, -78°C or CAN, CH_3CN/H_2O.
8
9
10   The synthesis of DAG-lactone analogues started from the racemic lactone having p-

11 methoxyphenyl (PMP) and benzyl (Bn) (**23**) or tert-butyldiphenylsilyl (TBDPS) (**24**) as protect-

12 ing groups (Scheme 4). Different aldehydes (RCHO, **20-22**) were reacted with the DAG-lactone

13 to form aldol intermediates and β-hydroxy-lactones were eliminated by aldol condensation to

14 give the corresponding olefins (**25-45**). After separation of geometric E/Z-isomers by silica col-

15 umn chromatography, parallel deprotection of **25**-**43** with BCl_3 or ceric ammonium nitrate (CAN)

16 afforded **46-64** and di-deprotections of TBDPS protected compounds **44-45** with TBAF afforded

17 **65-66**. The compounds were individually converted to the corresponding DAG-lactones having

18 different R_1-alkyl side chains by conventional coupling methods (**90-91**). Target compounds **86-**

19 **89**, **92-106** were obtained from additional deprotection of **67-85** using BCl_3 or CAN.

20 **2.2. Biological Activity**

21   Diacylglycerol lactones **86**-**106** were prepared and investigated. For the biological studies,

22 we selected the classical PKC isoform PKC-α as the standard for comparison, since it has been

23 used as the standard PKC isoform against which all the DAG-lactones have routinely been char-

24 acterized in our previous studies. The interaction of the target DAG-lactones with PKC-α and

25 PKC-ε was assessed, as before, by measurement of the ability of the ligands to compete for bind-

1 ing of [20-³H] phorbol 12, 13-dibutylate (PDBU) to recombinant PKC [24]. The IC_{50} values

2 were determined by least squares fit of the data points to the theoretical competition curve, and

3 the *Ki* values for inhibition of binding were calculated from the corresponding IC_{50} values (Table

4 2 and Table 3).

5   Our initial objective was to examine the possible selectivity of the DAG-lactones for

6 PKC-ε under standard lipid conditions, viz. 100 μg/ml phosphatidylserine. We determined the

7 binding affinities for PKC-α and PKC-ε and we calculated the Ki ratios for PKC-α/PKC-ε of all

8 compounds (Table 2, Table 3 and Table 4). Evaluation of the elements contributing to the relative

9 structure activity relations focused on geometry (E or Z), position of substitution (sn-1 or sn-2),

10 and lipophilicities of the compounds.

11   The binding affinities of ligands for different PKC isozymes may show different depend-

12 ence on the lipid composition of the membranes with which the PKC is associated. We therefore

13 evaluated the ligand selectivity not only under our standard assay conditions, 100 μg/ml of phos-

14 phatidylserine, which provides a highly anionic surface, but also using 100 μg/ml of a lipid mix-

15 ture   [1-palmutoyl-2-oleoyl-sn-glycero-3-phosphocholine(POPC)/1-palmitoyl-2-oleoyl-sn-

16 glycero-3-phosphoethanolamine(POPE)/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine

17 (POPS)/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol(POPI)/ Cholesterol (61:21:4:7:6)], a

18 much less anionic lipid composition approximating that of the nuclear membrane.

19   Table 2 displays binding affinities of DAG-lactones under standard (100% phosphatidyl-

20 serine) conditions. Most of the compounds showed modestly stronger binding affinity for PKC-ε

21 than for PKC-α. The compounds with the strongest PKC-ε binding affinities were characterized

22 as having an *E*-geometry with a *sn*-1 carbonyl substituted with a branched alkyl chain or an un-

23 saturated alkyl chain (Table **2**, compounds **95** and **104**). The best, albeit limited PKCε selectivity

24 was seen for the *sn*-2 carbonyl substituted with a saturated alkyl chain (cyclo- **103,** branched **104**,

25 linear **105** and **106**).

26

1   The PKC-ε selectivity of the compounds was further investigated for the nuclear mem-

2   brane mimetic assay system (Table 3). The changes resulting from lipid composition were sub-

3   stantial, particularly for compound **104**. The difference in lipid composition led to a reduction in

4   overall binding affinity and caused a different selectivity pattern to emerge. Compounds **91, 97,**

5   **99**, and **104** showed over a 3-fold enhanced selectivity (Table 3). In particular, compound **104**

6   retained its affinity to PKC-ε and showed the highest selectivity (32-fold) under the nuclear

7   membrane mimetic assay conditions (Table 3). The *E*-isomers having an *sn*-1 carbonyl substitut-

8   ed with an unsaturated alkyl chain showed good binding affinities and selectivity in this system.

9   A partial correlation with lipophilicity was observed among the compounds having over 5-fold

10 selectivity.

11 Another important observation was the clear disparities in selectivity shown by the two

12 geometrical isomers (Table 4), with the *E*-isomer being favored particularly in the nuclear mem-

13 brane mimetic assay conditions.

14 **3. Conclusion**

15 In conclusion, different types of alkyl chains derived from linoleic acid were introduced

16 as substituents for the DAG-lactone and their effects on selectivity for PKC-ε relative to PKC-α

17 was explored. Because cells contain a variety of membranes with different compositions, we also

18 assessed the influence of membrane lipid contribution on the measured isozyme selectivity. Most

19 of the compounds showed at least modest PKC-ε selectivity with a number approaching 5-fold in

20 the presence of the nuclear lipid mixture. The most dramatic example of selectivity, 32-fold, was

21 not with any of the linoleic derivative substituted DAG-lactones, however, suggesting that the

22 incorporation of the linoleic acid motif into the DAG-lactone did not confer the hoped for selec-

23 tivity.

24 Structure activity relationships were assessed for selected compounds showing the great-

25 er extents of selectivity for PKC-ε. When 100% phosphatidylserine was used as the lipid, the *E*-

26 conformation was preferred for compounds in which the *sn*-2 carbonyl was substituted with a

saturated alkyl chain (branched > linear > cyclo). In contrast, in the presence of the nuclear membrane mimetic lipids, *sn*-1 substituted compounds with an *E*-conformation showed PKC-ε selectivity regardless of whether the alkyl chains were saturated or unsaturated.

The most selective compound under both lipid conditions was (E)-(2-(hydroxymethyl)-4-(3-isobutyl-5-methylhexylidene)-5-oxotetrahydrofuran-2-yl) methyl pivalate **104,** which has the *sn*-2 carbonyl substituted with a saturated-branched alkyl chain with an *E*-conformation. Compound **104** showed a dramatic increase of selectivity (8-fold in the presence of phosphatidylserine, 32-fold in the presence of the nuclear membrane mimetic lipid) in the nuclear membrane conditions, reflecting that its binding affinity for PKC-α was significantly weaker under those conditions while its affinity for PKC-ε was largely retained.   In contrast, the other compounds showed reduced binding affinities both for PKC-α and PKC-ε. This result suggests that the lipid composition of the nuclear membrane enhanced the binding affinity to PKC-ε for **104**, reflecting enhanced interactions between the DAG-lactone side chain and the protein-membrane interface. The diverse affinity patterns of compounds from this work provide guidance for future approaches. In particular, the high selectivity of **104** suggests that further exploration of this class of DAG-lactones may be productive for obtaining PKC-ε specific compounds and understanding of factors driving subcellular localization of PKC isoforms. Naturally, validation of the selectivity of the optimal PKC-ε selective ligand will ultimately require characterization relative to the complete range of targets for DAG and phorbol esters, e.g. PKC family members, RasGRP, the chimaerins, and include measures of activity in intact cells.

4. Experimental

4.1. Chemistry

All chemical reagents were commercially available. Silica gel column chromatography was performed on silica gel 60, 230-400 mesh, Merck. Nuclear magnetic resonance (1H-NMR) spectra

were recorded on a JEOL JNM-LA 300 and a Bruker Avance 400 MHz FT-NMR spectrometer.

Chemical shifts are reported in ppm units with Me_4Si as a reference standard. Mass spectra were

recorded on a VG Trio-2 GC-MS and a 6460 Triple Quad LC/MS. Elemental analyses were per-

formed with an EA 1110 Automatic Elemental Analyzer, CE Instruments.

4.1.1. Preparation of alkyl side chains.

4.1.1.1. 8-(3-((3-Pentyloxiran-2-yl)methyl)oxiran-2-yl)octanoic acid (2)

A solution of linoleic acid **1** (500 mg, 1.783 mmol) and *meta*-chloroperoxybenzoic acid (1.8 g,

10.698 mmol) in 10 ml of CH_2Cl_2 was reacted at 0°C for 3 h. The excess reagent was decom-

posed by addition of aqueous Na_2CO_3 and stirring of the mixture for 1 h, after which the product

was isolated by CH_2Cl_2 extraction. The organic layer was washed with saturated aqueous sodium

bicarbonate and saturated brine, dried with $MgSO_4$, and evaporated. The crude product was puri-

fied by silica gel flash column chromatography (n-hexane/EtOAc, 4:1) and **2** (469 mg, 82%) was

obtained as a white solid.

4.1.1.2. Methyl (9Z,12Z)-octadeca-9,12-dienoate (3)

Thionyl chloride (0.5ml, 6.239 mmol) was added dropwise to commercially available linoleic

acid **1** (700mg, 2.495 mmol) dissolved in MeOH at 0°C. The reaction was stirred at room tem-

perature and monitored by TLC. Upon completion, H_2O was added and the reaction mixture was

concentrated *in vacuo*. The resulting solution was extracted with ethyl acetate, dried over $MgSO_4$,

and concentrated *in vacuo*. The crude product was purified by silica gel flash column chromatog-

raphy (n-hexane/EtOAc, 10:1) and **3** (712 mg, 96%) was obtained as a brown oil.

4.1.1.3. Methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate (5)

To a solution of linoleic acid methyl ester **3** (1 g, 3.395 mmol) in CH_2Cl_2, a 1.1 M n-hexane solu-

tion of diethyl zinc (7 ml, 40.751 mmol) was added under a N_2 atmosphere with cooling with an

ice-water bath (-5°C to 0°C) and was stirred for 1 h. Diiodomethane (7 ml, 81.502 equiv.) was

then added and the mixture was stirred at ambient temperature overnight. After removal of sol-

vent by evaporation, the product was extracted by ethyl acetate (EA) and purified by chromatog-

raphy on silica gel to give methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate **4**

(969 mg, 88%) as an oil. A mixture of this ester **4**, 1N LiOH (6.6 mL), and dioxane was stirred at

60°C overnight. The product was purified by acid-base workup with 1N HCl and 1N NaOH and

5 (740mg, 80%) was obtained as an oil.

4.1.1.4.   Octadeca-9,11-diynoic acid (10)

Copper (I) chloride (8.8 mg, 0.089 mmol.) was added to a 30% w/v n-BuNH$_2$ aqueous solution

(10 ml) at room temperature, which resulted in the formation of a blue solution. A few crystals of

hydroxylamine hydrochloride was added to discharge the blue color. Dec-9-ynoic acid **9** (300mg,

1.78 mmol) was then added neat, and the mixture was stirred at 0°C for 10 min by which time

the formation of a bright yellow precipitate (probably the alkynyl cuprate) was observed. Bromo-

alkyne **6** (404 mg, 2.14 mmol) dissolved in diethyl ether was then added to the cooled reaction

mixture and the cooling bath was removed after 10-15 min. Occasional addition of a small

amount of hydroxylamine hydrochloride was necessary to keep the color of the reaction light

yellow. The reaction mixture was stirred at room temperature for 2 h during which more crystals

of hydroxylamine hydrochloride were added whenever the reaction mixture started to turn blue

or light green. The reaction was then quenched and adjusted to pH ~2 by adding 1N HCl and the

organic compounds were extracted with ethyl acetate 3 times.   The combined layer was dried

over Na$_2$SO$_4$ and concentrated *in vacuo*. The crude product was purified by silica gel flash col-

umn chromatography (n-hexane/EtOAc, 4:1) and **10** (423 mg, 86%) was obtained as a yellow oil.

4.1.1.4.1. 1-Bromohept-1-yne (7)

The terminal alkyne **6** (1ml, 6.350 mmol) was dissolved in acetone. N-bromosuccinimide (1.4 g,

1 7.866 mmol) and AgNO$_3$ (108 mg, 0.635 mmol) were added to the resulting solution in this or-

2 der, and the mixture was stirred at room temperature for 3 h, until complete consumption of the

3 starting material according to TLC. It was then poured into iced water. The aqueous layer was

4 extracted with pentane (3 times), and the combined organic extracts were dried over MgSO$_4$, fil-

5 tered, and the solvent removed by evaporation under reduced pressure. The residue was purified

6 by silica gel flash column chromatography (n-hexane/EtOAc, 10:1) to yield bromo-alkyne **7**

7 (1.07 g, 89%) was obtained as a colorless oil.

8

9 **4.1.1.4.2. Dec-9-ynoic acid (9)**

10 To a solution of 9-decyn-1-ol **8** (5 ml, 28.20 mmol) in acetone at -5°C was slowly added chromic

11 acid solution prepared from CrO$_3$ (4.23 g, 42.30 mmol), water (4 ml), and conc. H$_2$SO$_4$ (3 ml) at

12 0°C. The mixture was then stirred for 2 h and left overnight at room temperature, after which it

13 was extracted with diethyl ether, washed with water and brine, dried over Na$_2$SO$_4$ and concen-

14 trated *in vacuo*. The residue was purified by silica gel flash column chromatography (n-

15 hexane/EtOAc, 7:1) to yield dec-9-ynoic acid **9** (3.8 g, 81%) as clear oil.

16

17 **4.1.2. Procedure for aldehyde preparation.**

18 **4.1.2.1. Alcohol preparation (17-19).**

19 Starting material (**2, 5, 8**) was dissolved in ether. Lithium aluminum hydride (2 equiv.) was add-

20 ed at 0°C and it was refluxed during 30 min. H$_2$O was added dropwise at 0°C; the solution was

21 extracted with ether and the combined extracts were dried over MgSO$_4$ and concentrated *in vac-*

22 *uo*. Finally, purification by silica gel flash column chromatography (n-hexane/EtOAc, 10:1) by

23 column chromatography yielded the alcohols (**17**-**19**).

24

25 **4.1.2.2. Aldehyde preparation (20-22).**

26 **Method A.** A solution of oxalyl chloride (1.5 equiv.) in distilled CH$_2$Cl$_2$ was cooled to -78°C,

and DMSO (3 equiv.) was carefully added under a N_2 atmosphere. After stirring for 15 min, a solution of alcohol (**17, 18**) in CH_2Cl_2 was added followed by Et_3N (6 equiv.). The cooling bath was removed, and the reaction mixture was allowed to warm to room temperature and stirred for 2.5 h. The solvent was removed under reduced pressure, and the residue was extracted with ethyl acetate. The extract was washed with saturated aqueous Na_2CO_3 solution and brine, and was then dried over anhydrous Na_2SO_4. After removal of the solvent under reduced pressure, the crude product was purified by silica gel flash column chromatography (n-hexane/EtOAc, 10:1) and the aldehyde (**20, 21**) was obtained as 75-80%.

Method B. To a solution of octadecan-1-ol **19** (560mg, 1equiv.) in CH_2Cl_2 was added Dess-Martin periodinane (1.3g, 1.5 equiv.) at room temperature and the resulting solution was stirred for 2 h at room temperature. The reaction mixture was quenched with a saturated solution of Na_2SO_3 and $NaHCO_3$. The reaction mixture was passed through a pad of Celite, the organic compound was extracted three times with CH_2Cl_2. The combined extracts were washed with water, dried over anhydrous $MgSO_4$, and filtrated. The filtrate was concentrated under vacuum, and purified by silica gel flash column chromatography (n-hexane/EtOAc, 10:1) by column chromatography to afford the stearaldehyde **22** (456mg, 82%).

4.1.3. General procedure for Alkylation

A stirred solution of lactone **23** (or **24**) (1 equiv.) in anhydrous THF (5 mL/mmol) was cooled to -78°C under nitrogen and treated dropwise with LiHMDS (3 equiv., 2 M solution in THF). The mixture was stirred at -78°C for 30-60 min and lithium enolate formation was detected by TLC (n-hexane/EtOAc, 4:1). A solution of the corresponding aldehyde (1.4 to 4 equiv.) in anhydrous THF (1 mL/mmol) was added dropwise to the enolate at the same temperature and stirring at -78°C was continued for 1.5-2 h. The reaction was warmed to room temperature and quenched by the slow addition of a saturated aqueous solution of ammonium chloride. The aqueous layer was extracted three times with Et_2O, and the combined organic extracts were washed three times with

water, twice with brine, dried over MgSO$_4$, and filtered. The filtrate was concentrated under vacuum to afford the crude alkylation reaction product, which was partially purified by silica gel flash column chromatography after eluting with the appropriate solvent. The obtained mixture of β-hydroxy-lactone diastereomers were typically used directly in the following step without further purification.

4.1.4. General procedure for Mesylation-Olefination

A solution of the alkylation product in CH$_2$Cl$_2$ at 0°C was treated with methanesulfonyl chloride (2 equiv.) and triethylamine (4 equiv.). The mixture was stirred at 0°C for 30 min and then for 2 h at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 5 equiv.) was added at 0°C, and the resulting solution was stirred overnight at ambient temperature. The reaction mixture was concentrated to a brown syrup and the residue was extracted with EtOAc followed by 1N HCl. The combined organic extracts were washed three times with water, twice with brine, dried over MgSO$_4$, and filtered. The combined organics were purified by silica gel flash column chromatography after eluting with the appropriate solvent.

4.1.5. General procedure for deprotection

4.1.5.1. PMP-deprotection

A stirred solution of the olefination product (1 equiv.) in acetonitrile/water (4/1) was treated with CAN (3 equiv.) while under nitrogen at 0°C, and the reaction was monitored by TLC. After 30 min, the reaction was quenched by addition of aqueous NaHCO$_3$ solution and the resulting solution was extracted with CH$_2$Cl$_2$, dried over MgSO$_4$, and concentrated in *vacuo*. It was purified by silica gel flash column chromatography (*n*-hexane/EtOAc, 2:1) and the deprotected compound was obtained.

4.1.5.2. Benzyl Deprotection

1   BCl$_3$ (3 equiv.) was added slowly to a stirred solution of the olefination product (1 equiv.) in

2   CH$_2$Cl$_2$ at -78°C. The reaction was monitored by TLC and quenched by addition of MeOH at

3   0°C. The reaction mixture was concentration *in vacuo* and purification by silica gel flash column

4   chromatography (*n*-hexane/EtOAc, 2:1) gave the desired deprotected compounds.

5

6   **4.1.5.3. TBDPS Deprotection**

7   TBAF (2 equiv.) was added slowly to a stirred solution of the olefination product (1 equiv.) in

8   THF at 0°C and stirring continued as the temperature was allowed to rise to room temperature.

9   The reaction was monitored by TLC and the solution was concentrated *in vacuo* upon completion

10   without further work-up. Purification by silica gel flash column chromatography (*n*-

11   hexane/EtOAc, 1:1) gave the desired de-protected diol-lactone.

12

13   **4.1.6. General procedure for Acylation**

14   A solution of mono-deprotected compound (1 equiv.) in CH$_2$Cl$_2$ was treated with Et$_3$N (3 equiv.)

15   and dimethylaminopyridine (DMAP, 2.5 equiv.) and reacted with the corresponding acid chloride

16   (RCOCl, 1.2-1.5 equiv.). The reaction was stirred at room temperature and monitored by TLC.

17   Upon completion, the reaction was concentrated *in vacuo* and purified by silica gel flash column

18   chromatography give the desired compound.

19

20   **4.1.6.1. Monoacylation (di-epoxy compounds, DEP-LA)**

21   A solution of **65** (or **66**) (1 equiv.) in CH$_2$Cl$_2$ was treated with EDC (1.1 equiv.) and dimethyla-

22   minopyridine (DMAP, 0.3 equiv.) and reacted with 8-(3-((3-pentyloxiran-2-yl)methyl)oxiran-2-

23   yl)octanoic acid (1.5 equiv.). The reaction was stirred at room temperature and monitored by

24   TLC. Upon completion, the reaction was terminated by adding H$_2$O. The organic layer was ex-

25   tracted with CH$_2$Cl$_2$, dried over MgSO$_4$, concentrated *in vacuo* and purified by silica gel flash

26   column chromatography (*n*-hexane/EtOAc, 4:1) to give the mono-substituted desired compound

90-91.

4.1.7. ((Z)-2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl-(9Z,12Z)-octadeca-9,12-dienoate (86)

Yield 63%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.24 (t, J = 7.76 Hz, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 5.39–5.30 (m, 4H, -C$\underline{H}$=C$\underline{H}$CH$_2$C$\underline{H}$=C$\underline{H}$-), 4.26 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.14 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.58-3.69 (dq, J = 12.00, 7.20, 6.56 Hz, 2H, HOC$\underline{H}_2$-), 2.88 (AB d, J = 16.44 Hz, 1H, H-3$_a$), 2.75 (t, J = 6.24 Hz, 2H, -CH=CHC$\underline{H}_2$CH=CH-), 2.72 (AB d, J = 16.44 Hz, 1H, H-3$_b$), 2.60 (t, J = 7.44 Hz, 2H, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 2.31 (t, J = 7.56 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$), 2.04 (q, J = 6.88 Hz, 4H, -C$\underline{H}_2$CH=CHCH$_2$CH=CHC$\underline{H}_2$-), 1.96 (m, 1H, $\underline{H}$OCH$_2$-), 1.71 (septet, J = 6.74 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.59 (m, 2H, Alkyl-C$\underline{H}_2$CH$_2$(O)COCH$_2$), 1.28 (m, 14H, CH$_3$(C$\underline{H}_2$)$_3$CH$_2$CH=CHCH$_2$CH=CHCH$_2$(C$\underline{H}_2$)$_4$CH$_2$-), 0.92 (d, J = 6.68 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz, 3H, C$\underline{H}_3$(CH$_2$)$_3$CH$_2$CH=CH-); MS (FAB) m/z 477 (M+H)

4.1.8. ((E)-2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl (9Z,12Z)-octadeca-9,12-dienoate (87)

Yield 76%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.78 (t, J = 7.76 Hz, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 5.39–5.30 (m, 4H, -C$\underline{H}$=C$\underline{H}$CH$_2$C$\underline{H}$=C$\underline{H}$-), 4.26 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.14 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.58-3.69 (dq, J = 12.00, 7.20, 6.56 Hz, 2H, HOC$\underline{H}_2$-), 2.73-2.81 (m, 3H, H-3$_a$, -CH=CHC$\underline{H}_2$CH=CH-), 2.62 (AB d, J = 17.04 Hz, 1H, H-3$_b$), 2.31 (t, J = 7.56 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$), 2.04 (q, J = 6.88 Hz, 4H, -C$\underline{H}_2$CH=CHCH$_2$CH=CHC$\underline{H}_2$-), 1.96 (m, 1H, $\underline{H}$OCH$_2$-), 1.71 (septet, J = 6.74 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.59 (m, 2H, Alkyl-C$\underline{H}_2$CH$_2$(O)COCH$_2$), 1.28 (m, 14H, CH$_3$(C$\underline{H}_2$)$_3$CH$_2$CH=CHCH$_2$CH=CHCH$_2$(C$\underline{H}_2$)$_4$CH$_2$-), 0.92 (d, J = 6.68 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz, 3H, C$\underline{H}_3$(CH$_2$)$_3$CH$_2$CH=CH-)-); MS (FAB) m/z 477

(M+H)

4.1.9. (Z)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate (88)

Yield 71%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.24 (t, J = 7.76 Hz, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.26 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.14 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.58-3.69 (dq, J = 12.1, 7.20, 6.56 Hz, 2H, HOC$\underline{H}_2$), 2.88 (AB d, J = 16.52 Hz, 1H, H-3$_a$), 2.69 (AB q, J = 16.44 Hz, 1H, H-3$_b$), 2.60 (t, J = 7.44 Hz, 2H, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 2.31 (t, J = 7.60 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$), 2.04 (t, J = 4.00 Hz, 1H, $\underline{H}$OCH$_2$), 1.69 (septet, J = 6.72 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.59 (m, 2H, Alkyl-C$\underline{H}_2$CH$_2$(O)COCH$_2$,), 1.37 (bs, 6H, Alkyl), 1.28 (bs, 12H, Alkyl), 1.10 (m, 2H, Alkyl), 0.92 (d, 6H, J = 6.60 Hz, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.87 (t, J = 6.44 Hz, 3H, C$\underline{H}_3$-Alkyl-(O)COCH$_2$), 0.75 (m, 2H, -C$\underline{H}$CH$_2$C$\underline{H}$-), 0.66 (m, 2H, -C$\underline{H}$CH$_2$C$\underline{H}$-), 0.57 (m, 2H, -CHC$\underline{H}_2$CH-), -0.30 (m, 2H, -CHC$\underline{H}_2$CH-); MS (FAB) m/z 505 (M+H)

4.1.10. (E)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate (89)

Yield 73%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.78 (t, J = 7.76 Hz, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.26 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.14 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.58-3.69 (dq, J = 12.1, 7.20, 6.56 Hz, 2H, HOC$\underline{H}_2$), 2.88 (AB d, J = 16.52 Hz, 1H, H-3$_a$), 2.69 (AB q, J = 16.44 Hz, 1H, H-3$_b$), 2.31 (t, J = 7.60 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$), 2.04 (m, 3H, $\underline{H}$OCH$_2$, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$),), 1.69 (septet, J = 6.72 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.59 (m, 2H, Alkyl-C$\underline{H}_2$CH$_2$(O)COCH$_2$,), 1.37 (bs, 6H, Alkyl), 1.28 (bs, 12H, Alkyl), 1.10 (m, 2H, Alkyl), 0.92 (d, 6H, J = 6.60 Hz, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.87 (t, J = 6.44 Hz, 3H, C$\underline{H}_3$-Alkyl-(O)COCH$_2$), 0.75 (m, 2H, -C$\underline{H}$CH$_2$C$\underline{H}$-), 0.66 (m, 2H, -CHCH$_2$CH-), 0.57 (m, 2H, -CHC$\underline{H}_2$CH-), -0.30 (m, 2H, -CHC$\underline{H}_2$CH-); MS (FAB) m/z 505 (M+H)

18

4.1.11. (Z)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl 8-(3-((3-pentyloxiran-2-yl)methyl)oxiran-2-yl)octanoate (90)

Yield 35%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.24 (t, J = 6.24 Hz, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.26 (AB d, J = 9.56 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.14 (AB d, J = 9.56 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.59-3.68 (m, 2H, HOC$\underline{H}_2$-), 3.09 (bs, 2H, -C$\underline{H}$(O)C$\underline{H}$-), 2.95 (bs, 2H, -C$\underline{H}$(O)C$\underline{H}$-), 2.78 (AB d, J = 13.00 Hz, 1H, H-3$_a$), 2.68 (AB d, J = 13.00 Hz, 1H, H-3$_b$), 2.60 (t, J = 5.72 Hz, 2H, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 2.31 (t, J = 5.96 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$-), 1.81 (m, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.70 (m, 3H, -CH(O)CHC$\underline{H}_2$CH(O)CH-), 1.31-1.40 (m, 20H, Alkyl), 0.92 (d, J = 5.28 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz, 3H, C$\underline{H}_3$-Alkyl-); MS (FAB) m/z 509 (M+H)

4.1.12. (E)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl 8-(3-((3-pentyloxiran-2-yl)methyl)oxiran-2-yl)octanoate (91)

Yield 32%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.24 (m, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.26 (AB d, J = 9.52 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.14 (AB d, J = 9.52 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.60-3.71 (dq, J = 9.66, 5.64, 5.24 Hz, 2H, HOC$\underline{H}_2$-), 3.09 (bs, 2H, -C$\underline{H}$(O)C$\underline{H}$-), 2.95 (bs, 2H, -C$\underline{H}$(O)C$\underline{H}$-), 2.78 (AB d, J = 14.60 Hz, 1H, H-3$_a$), 2.62 (AB d, J = 14.60 Hz, 1H, H-3$_b$), 2.31 (t, J = 6.00 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$-), 2.11 (m, 1H, $\underline{H}$OCH$_2$-), 2.06 (m, 2H, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 1.81 (m, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.70 (m, 3H, -CH(O)CHC$\underline{H}_2$CH(O)CH-), 1.44-1.49 (m, 8H, Alkyl), 1.22-1.32 (m, 12H, Alkyl), 0.92 (d, J = 5.28 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz, 3H, C$\underline{H}_3$-Alkyl-); MS (FAB) m/z 509 (M+H)

4.1.13. (Z)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl stearate (92)

19

Yield 60%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.24 (t, J = 7.72 Hz, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$),

4.26 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.14 (AB d, J = 11.8 Hz, 1H, Alkyl-

(O)COCH$\underline{H}$), 3.64 (m, 2H, HOC$\underline{H}_2$-), 2.90 (AB d, J = 16.34 Hz, 1H, H-3$_a$), 2.69 (AB d, J =

16.34 Hz, 1H, H-3$_b$), 2.60 (t, J = 7.48 Hz, 2H, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 2.30 (t, J = 7.44 Hz, 2H,

Alkyl-C$\underline{H}_2$(O)COCH$_2$-), 2.04 (m, 1H, $\underline{H}$OCH$_2$-), 1.71 (m, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.58 (m,

2H), 1.23 (m, 28H, Alkyl), 0.92 (d, J = 6.64 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz,

3H, C$\underline{H}_3$-Alkyl-); MS (FAB) m/z 481 (M+H)

4.1.14. (E)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl

stearate (93)

Yield 60%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.78 (m, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.26 (AB d,

J = 11.8 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.15 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.66 (q,

J = 11.04 Hz, 2H, HOC$\underline{H}_2$-), 2.79 (AB d, J = 16.00Hz, 1H, H-3$_a$), 2.63 (AB d, J = 16.00 Hz, 1H,

H-3$_b$), 2.30 (t, J = 7.64 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$-), 2.04 (m, 3H, $\underline{H}$OCH$_2$-,

>C=CHC$\underline{H}_2$CH(CH$_3$)$_2$),), 1.80 (septet, J = 6.74 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.23 (m, 32H,

Alkyl), 0.92 (d, J = 6.64 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz, 3H, C$\underline{H}_3$-Alkyl-);

MS (FAB) m/z 481 (M+H)

4.1.15. (Z)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl

3-isobutyl-5-methylhexanoate (94)

Yield 59%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.26 (tt, J = 7.28, 2.3 Hz, 1H,

>C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.20 (AB q, J = 11.9 Hz, 2H, Alkyl-(O)COC$\underline{H}_2$), 3.66 (AB q, J = 12.2

Hz, 2H, HOC$\underline{H}_2$-), 2.90 (AB d, J = 16.4Hz, 1H, H-3$_a$), 2.72 (AB d, J = 16.4 Hz, 1H, H-3$_b$), 2.62

(m, 2H, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 2.24 (m, 2H, ((CH$_3$)$_2$CHCH$_2$)$_2$CHC$\underline{H}_2$(O)COCH$_2$-), 1.80 (m, 1H,

>C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.68-1.78 (m, 1H, ((CH$_3$)$_2$CHCH$_2$)$_2$C$\underline{H}$CH$_2$(O)COCH$_2$-), 1.58-1.62 (m,

2H, ((CH$_3$)$_2$C$\underline{H}$CH$_2$)$_2$CHCH$_2$(O)COCH$_2$-), 1.03 (m, 4H, ((CH$_3$)$_2$CHC$\underline{H}_2$)$_2$CHCH$_2$(O)COCH$_2$-),

0.96 (d, J = 6.70 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (m, 12H, ((C$\underline{H}_3$)$_2$CHCH$_2$)$_2$CHCH$_2$(O)COCH$_2$-); MS (FAB) m/z 383 (M+H)

4.1.16. (E)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl 3-isobutyl-5-methylhexanoate (95)

Yield 62%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.80 (tt, J = 7.70, 2.3 Hz, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.31 (AB d, J = 3.12 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.17 (AB d, J = 2.76 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.68 (m, 2H, HOC$\underline{H}_2$-), 2.83 (AB d, J = 17.01 Hz, 1H, H-3$_a$), 2.65 (AB d, J = 17.01 Hz, 1H, H-3$_b$), 2.22-2.24 (m, 2H, ((CH$_3$)$_2$CHCH$_2$)$_2$CHC$\underline{H}_2$(O)COCH$_2$-), 2.04 (m, 3H, $\underline{H}$OCH$_2$-, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 1.82 (m, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.61 (m, 1H, ((CH$_3$)$_2$CHCH$_2$)$_2$C$\underline{H}$CH$_2$(O)COCH$_2$-), 1.58 (m, 2H, ((CH$_3$)$_2$C$\underline{H}$CH$_2$)$_2$CHCH$_2$(O)COCH$_2$-), 1.03 (m, 4H, ((CH$_3$)$_2$CHC$\underline{H}_2$)$_2$CHCH$_2$(O)COCH$_2$-), 0.96 (d, J = 6.70 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (m, 12H, ((C$\underline{H}_3$)$_2$CHCH$_2$)$_2$CHCH$_2$(O)COCH$_2$-); MS (FAB) m/z 383 (M+H)

4.1.17. (Z)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl octadec-9-ynoate (96)

Yield 80%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.24 (m, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.26 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.14 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.61 (q, J = 12.2 Hz, 2H, HOC$\underline{H}_2$-), 2.88 (AB d, J = 17.32, 2.2 Hz, 1H, H-3$_a$), 2.63 (AB d, J = 17.32, 2.2 Hz, 1H, H-3$_b$), 2.60 (tt, J = 7.24, 2.0 Hz, 2H, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 2.30 (t, J = 7.52 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$-), 2.12 (t, J = 6.24 Hz, 4H, -C$\underline{H}_2$C≡CC$\underline{H}_2$-), 1.71 (septet, J = 6.72 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.59 (m, 7H), 1.44 (m, 5H), 1.25 (m, 11H), 0.92 (d, J = 6.68 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz, 3H, C$\underline{H}_3$-Alkyl); MS (FAB) m/z 477 (M+H)

4.1.18. (E)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl octadec-9-ynoate (97)

21

Yield 77%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.74 (m, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.26 (AB d, J = 11.88 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.17 (AB d, J = 11.88 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.66 (m, 2H, HOC$\underline{H}_2$-), 2.81 (AB d, J = 17.19 Hz, 1H, H-3$_a$), 2.64 (AB d, J = 17.19 Hz, 1H, H-3$_b$), 2.32 (t, J = 7.68 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$-), 2.13 (t, J = 6.24 Hz, 4H, -C$\underline{H}_2$C≡CC$\underline{H}_2$-), 2.07 (m, 2H, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 1.71 (septet, J = 6.72 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.60 (m, 7H), 1.27-1.47 (m, 21H), 0.95 (d, J = 6.60 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz, 3H, C$\underline{H}_3$-Alkyl); MS (FAB) m/z 477 (M+H)

4.1.19. (Z)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl octadeca-9,11-diynoate (98)

Yield 74%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.25 (tt, J = 7.82, 7.78 Hz, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.25 (AB d, J = 12.00 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.14 (AB d, J = 12.00 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.65 (dq, J = 7.2, 6.52 Hz, 2H, HOC$\underline{H}_2$-), 2.88 (AB d, J = 16.52 Hz, 1H, H-3$_a$), 2.70 (AB d, J = 16.52 Hz, 1H, H-3$_b$), 2.60 (tt, J = 6.84, 2.04, 2.00 Hz, 2H, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 2.30 (t, J = 7.48 Hz, 2H, Alkyl-C$\underline{H}_2$(O)COCH$_2$-), 2.22 (t, J = 6.80 Hz, 4H, CH$_3$(CH$_2$)$_4$C$\underline{H}_2$-C≡C-C≡C-C$\underline{H}_2$-), 2.06 (m, 1H, $\underline{H}$OCH$_2$-), 1.71 (septet, J = 6.72 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.59 (m, 2H, Alkyl), 1.49 (m, 4H), 1.33-1.39 (m, 3H), 1.22-1.29 (m, 3H, Alkyl), 0.93 (d, J = 6.68 Hz, 6H, >C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz, 3H, C$\underline{H}_3$-Alkyl); MS (FAB) m/z 473 (M+H)

4.1.20. (E)-(2-(Hydroxymethyl)-4-(3-methylbutylidene)-5-oxotetrahydrofuran-2-yl)methyl octadeca-9,11-diynoate (99)

Yield 74%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.78 (tt, J = 7.80, 7.68 Hz, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_3$)$_2$), 4.26 (AB d, J = 11.84 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.15 (AB d, J = 11.84 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.66 (dq, J = 7.00, 6.44 Hz, 2H, HOC$\underline{H}_2$-), 2.79 (AB d, J = 16.81 Hz, 1H, H-3$_a$), 2.62 (AB d, J = 16.81 Hz, 1H, H-3$_b$), 2.30 (t, J = 7.34 Hz, 2H, Alkyl-

C$\underline{H}_2$(O)COCH$_2$-), 2.22 (t, J = 6.92 Hz, 4H, CH$_3$(CH$_2$)$_4$C$\underline{H}_2$-C≡C-C≡C-C$\underline{H}_2$-), 2.06 (m, 3H,

$\underline{H}$OCH$_2$-, >C=CHC$\underline{H}_2$CH(CH$_3$)$_2$), 1.80 (septet, J = 6.64 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_3$)$_2$), 1.49

(m, 4H, Alkyl), 1.33-1.39 (m, 3H), 1.22-1.29 (m, 9H, Alkyl), 0.93 (d, J = 6.64 Hz, 6H,

>C=CHCH$_2$CH(C$\underline{H}_3$)$_2$), 0.86 (t, J = 6.08 Hz, 3H, C$\underline{H}_3$-Alkyl); MS (FAB) m/z 473 (M+H)

4.1.21. ((Z)-2-(Hydroxymethyl)-4-((9Z,12Z)-octadeca-9,12-dien-1-ylidene)-5 oxotetrahydro-furan-2-yl)methyl pivalate (100)

Yield 54%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.22 (t, J = 7.76 Hz, 1H, >C=C$\underline{H}$(CH$_2$)$_7$-), 5.32 (m, 4H, -C$\underline{H}$=C$\underline{H}$CH$_2$C$\underline{H}$=C$\underline{H}$CH$_2$-), 4.28 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.12 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.58-3.69 (dq, J = 12.1, 7.04, 6.64 Hz, 2H, HOC$\underline{H}_2$), 2.80 (AB q, J = 14.64 Hz, 1H, H-3$_a$), 2.61-2.76 (m, 4H, H-3$_b$,>C=CHC$\underline{H}_2$-, $\underline{H}$OCH$_2$-), 2.02 (m, 4H, -C$\underline{H}_2$CH=CHCH$_2$CH=CHC$\underline{H}_2$-), 1.72 (m, 2H, -CH$_2$CH=CHC$\underline{H}_2$CH=CHCH$_2$-), 1.28 (bs, 16H, >C=CH(C$\underline{H}_2$)$_5$CH$_2$-, -(C$\underline{H}_2$)$_3$CH$_3$), 1.17 (s, 9H, (C$\underline{H}_3$)$_3$(O)COCH$_2$), 0.85 (m, 3H, Alkyl-C$\underline{H}_3$); MS (FAB) m/z 477 (M+H)

4.1.22. ((E)-2-(Hydroxymethyl)-4-((9Z,12Z)-octadeca-9,12-dien-1-ylidene)-5 oxotetrahydro-furan-2-yl)methyl pivalate (101)

Yield 50%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.75 (m, 1H, >C=C$\underline{H}$(CH$_2$)$_7$-), 5.32 (m, 4H, -C$\underline{H}$=C$\underline{H}$CH$_2$C$\underline{H}$=C$\underline{H}$CH$_2$-), 4.28 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COC$\underline{H}$H), 4.12 (AB d, J = 11.8 Hz, 1H, Alkyl-(O)COCH$\underline{H}$), 3.58-3.69 (dq, J = 12.1, 7.04, 6.64 Hz, 2H, HOC$\underline{H}_2$-), 2.80 (AB d, J = 17.08 Hz, 1H, H-3$_a$), 2.63 (AB d, J = 17.08 Hz, 1H, H-3$_b$), 2.14 (m, 2H, >C=CHC$\underline{H}_2$-), 2.02 (m, 4H, -C$\underline{H}_2$CH=CHCH$_2$CH=CHC$\underline{H}_2$-), 1.72 (m, 2H, -CH$_2$CH=CHC$\underline{H}_2$CH=CHCH$_2$-), 1.28 (bs, 16H, >C=CH(C$\underline{H}_2$)$_5$CH$_2$-, -(C$\underline{H}_2$)$_3$CH$_3$), 1.17 (s, 9H, (C$\underline{H}_3$)$_3$(O)COCH$_2$), 0.85 (m, 3H, Alkyl-C$\underline{H}_3$); MS (FAB) m/z 477 (M+H)

4.1.23. (Z)-(2-(Hydroxymethyl)-5-oxo-4-(8-(2-((2-

pentylcyclopropyl)methyl)cyclopropyl)octylidene)tetrahydrofuran-2-yl)methylpivalate (102)

Yield 55%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.22 (t, J = 7.36 Hz, 1H, >C=C$\underline{H}$(CH$_2$)$_7$-), 4.25 (AB d, J = 12.00 Hz, 1H, (CH$_3$)$_3$(O)COC$\underline{H}$H-), 4.11 (AB d, J = 12.00 Hz, 1H, (CH$_3$)$_3$(O)COCH$\underline{H}$-), 3.63 (dq, J = 18.96, 7.24, 6.60 Hz, 2H, HO-C$\underline{H}_2$), 2.88 (AB d, J = 15.54 Hz, 1H, H-3$_a$), 2.67 (m, 3H, H-3$_b$, >C=CHC$\underline{H}_2$(CH$_2$)$_6$-), 2.04 (t, J = 7.2 Hz, 1H, $\underline{H}$O-CH$_2$-), 1.11-1.46 (m, 30H, Alkyl), 0.82 (m, 3H, -Alkyl-C$\underline{H}_3$); MS (FAB) m/z 505 (M+H)

4.1.24. (E)-(2-(Hydroxymethyl)-5-oxo-4-(8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octylidene)tetrahydrofuran-2-yl)methylpivalate (103)

Yield 60%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.75 (t, J = 7.2 Hz, 1H, >C=C$\underline{H}$(CH$_2$)$_7$-), 4.28 (AB d, J = 12.00 Hz, 1H, (CH$_3$)$_3$(O)COC$\underline{H}$H-), 4.13 (AB d, J = 12.00 Hz, 1H, (CH$_3$)$_3$(O)COCH$\underline{H}$-), 3.59-3.72 (dq, J = 14.52, 6.96, 6.48 Hz, 2H, HO-C$\underline{H}_2$-), 2.80 (AB d, J = 17.24 Hz, 1H, H-3$_a$), 2.64 (AB-d, J = 17.24 Hz, 1H, H-3$_b$), 2.15 (m, 2H, >C=CHC$\underline{H}_2$(CH$_2$)$_6$-), 2.05 (t, J = 6.84 Hz, $\underline{H}$O-CH$_2$), 1.10-1.52 (m, 22H, Alkyl), 1.05 (s, 9H, (C$\underline{H}_3$)$_3$(O)COCH$_2$-), 0.87 (m, 3H, -Alkyl-C$\underline{H}_3$), 0.64-0.69 (m, 2H) , 0.56-0.61 (m, 1H); MS (FAB) m/z 505 (M+H)

4.1.25. (E)-(2-(Hydroxymethyl)-4-(3-isobutyl-5-methylhexylidene)-5-oxotetrahydrofuran-2-yl)methyl pivalate (104)

Yield 59%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.78 (m, 1H, >C=C$\underline{H}$CH$_2$CH(CH$_2$(CH$_3$)$_2$)$_2$), 4.29 (AB d, J = 11.8 Hz, 1H, (CH$_3$)$_3$(O)COC$\underline{H}$H-), 4.11 (AB d, J = 11.8 Hz, 1H, (CH$_3$)$_3$(O)COCH$\underline{H}$-), 3.59-3.72 (dq, J = 13.2, 7.16, 6.6 Hz, 2H, HO-C$\underline{H}_2$), 2.79 (AB d, J = 17.1 Hz, H-3$_a$), 2.62 (AB d, J = 17.1 Hz, 1H, H-3$_b$), 2.11 (t, J = 6.04 Hz, 2H, >C=CHC$\underline{H}_2$CH(CH$_2$(CH$_3$)$_2$)$_2$), 2.03 (t, J = 6.88 Hz, 1H, $\underline{H}$O-CH$_2$), 1.69 (pentet, J = 6.56 Hz, 1H, >C=CHCH$_2$C$\underline{H}$(CH$_2$(CH$_3$)$_2$)$_2$), 1.06 (septet, J = 6.72 Hz, 2H, >C=CHCH$_2$CH(CH$_2$C$\underline{H}$(CH$_3$)$_2$)$_2$), 1.17 (s, 9H, (C$\underline{H}_3$)$_3$(O)COCH$_2$-), 1.04-1.10 (m, 4H, >C=CHCH$_2$CH(C$\underline{H}_2$CH(CH$_3$)$_2$)$_2$), 0.85 (d, J = 6.44 Hz, 12H, >C=CHCH$_2$CH(CH$_2$CH(C$\underline{H}_3$)$_2$)$_2$); MS (FAB) m/z 383 (M+H)

4.1.26. (Z)-(2-(Hydroxymethyl)-4-octadecylidene-5-oxotetrahydrofuran-2-yl)methyl

pivalate (105)

Yield 68%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.22 (tt, 1H, >C=C$\underline{H}$(CH$_2$)$_{16}$CH$_3$), 4.25 (AB d, J = 11.8 Hz, 1H, (CH$_3$)$_3$(O)COC$\underline{H}$H), 4.11 (AB d, J = 11.8 Hz, 1H, (CH$_3$)$_3$(O)COCH$\underline{H}$), 3.63 (dq, J = 6.76, 6.08Hz, 2H, HOC$\underline{H}_2$), 2.87 (AB q, J = 16.68 Hz, 1H, H-3$_a$), 2.66-2.71 (m, 3H, H-3$_b$,>C=CHC$\underline{H}_2$-), 2.09 (t, 1H, $\underline{H}$OCH$_2$-), 1.23 (s, 30H, >C=CHCH$_2$(C$\underline{H}_2$)$_{15}$CH$_3$), 1.17 (s, 9H, (C$\underline{H}_3$)$_3$(O)COCH$_2$), 0.85 (t, J = 7.04 Hz, 3H, Alkyl-C$\underline{H}_3$); MS (FAB) m/z 481 (M+H)

4.1.27. (E)-(2-(Hydroxymethyl)-4-octadecylidene-5-oxotetrahydrofuran-2-yl)methyl

pivalate (106)

Yield 62%, Oil; ^{1}H NMR (CDCl$_3$, 400MHz) δ 6.75 (tt, J = 3.12, 3.08, 2.96 Hz, 1H, >C=C$\underline{H}$(CH$_2$)$_{16}$CH$_3$), 4.27 (AB d, J = 11.8 Hz, 1H, (CH$_3$)$_3$(O)COC$\underline{H}$H), 4.12 (AB d, J = 11.8 Hz, 1H, (CH$_3$)$_3$(O)COCH$\underline{H}$), 3.66 (dq, J = 7.04, 6.6Hz, 2H, HOC$\underline{H}_2$), 2.80 (AB q, J = 16.88 Hz, 1H, H-3$_a$), 2.63 (AB d, J = 16.88 Hz, 1H, H-3$_b$), 2.14 (m, 3H, $\underline{H}$OCH$_2$-, >C=CHC$\underline{H}_2$(CH$_2$)$_{15}$CH$_3$), 1.23 (s, 30H, >C=CH(C$\underline{H}_2$)$_{15}$CH$_3$), 1.17 (s, 9H, (C$\underline{H}_3$)$_3$(O)COCH$_2$), 0.85 (t, J = 7.04 Hz, 3H, Alkyl-C$\underline{H}_3$); MS (FAB) m/z 481 (M+H)

References

[1]   K. Nacro, B. Bienflait, J. Lee, K-C. Han, J-H Kang, S. Benzaria, N. E. Lewin, D. K. , P. M. Blumberge, V. E. Marquez, Conformationally Constrained Analogues of Diacylglyc-

erol (DAG). 16. How Much Structural Complexity Is Necessary for Recognition and High Binding Affinity to Protein Kinase C?, J. Med. Chem. 43 (2000) 921-944.

[2] D.R. Dries, L.L Gallegos, A.C. Newton, A Single Residue in the C1 Domain Sensitizes Novel Protein Kinase C Isoforms to Cellular Diacylglycerol Production, J. Bio. Chem. 282 (2007) 826-830.

[3] S.C. Kiley, S. Jaken, R. Whelan, P. J. Parker, Intracellular targeting of protein kinase C isozymes: functional implications, Biochem. Soc. Trans. 23 (1995) 601-605.

[4] D. Duan, D. M. Sigano, J. A. Kelly, C. C. Lai, N. E. Lewin, N. Kedei, M. L. Peach, J. Lee, T. P. Abeyweera, S. A. Rotenberg, H. Kim, Y. H. Kim, S. E. Kazzouli, J-U Chung, H. A. Young, M. R. Young, A. Baker, N. H. Colburn, A. Haimovitz-Friedman, J-P. Truman, D. A. Parrish, J. R. Deschamps, N. A. Perry, R. J. Surawski, P. M. Blumberg, V. E. Marquez, Conformationally Constrained Analogues of Diacylglycerol. 29. Cells Sort Diacylglycerol-Lactone Chemical Zip Codes to Produce Diverse and Selective Biological Activities, J. Med. Chem. 51 (2008) 5198-5220.

[5] Y.Nishizuka, Protein kinase C and lipid signaling for sustained cellular responses, FASEB J., 9 (1995) 484-496.

[6] E.M. Griner, M.G. Kazanietz, Protein Kinase C and other Diacylglycerol Effectors in Cancer.　Nat. Rev. Cancer 7(2007)281-294.

[7] P.M. Blumberg, N. Kedei, N.E. Lewin, D. Yang, G. Czifra, Y. Pu, M.L. Peach, V.E. Marquez, Wealth of opportunity – the C1 domain as a target for drug development. Curr. Drug Targets 9(2008)641-652.

[8] S. Jaken, Protein Kinase C isozymes and substrates, Curr Opin Cell Biol 8 (1996) 168-173.

[9] C.A. Farah, W.S. Sossin, The role of C2 domains in PKC signaling.　Adv. Exp. Med. Biol.　740(2012)663-683.

[10] Y. Akita, Protein Kinase C-ε (PKC-ε): Its Unique Structure and Function, J. Biochem.

1   132 (2002) 847-852.

[11] R. Prekeris, M. W. Mayhew, J. B. Cooper, D. M. Terrian, Identification and Localization of an Actin-binding Motif That Is Unique to the Epsilon Isoform of Protein Kinase C and Participates in the Regulation of Synaptic Function, J. Cell. Biol. 132 (1996) 77-90.

[12] K. Inagaki, E. Churchill, D. Mochly-Rosen, Epsilon protein kinase C as a potential therapeutic target for the ischemic heart, Cardiovascular Research 70 (2006) 222-230.

[13] R. Zeidman, U. Troller, A. Raghunath, S. Pahlman, C. Larsson, Protein Kinase C ε actin-binding site is important for neurite outgrowth during neuronal differentiation, Mol. Biol. Cell 13 (2002) 12-24.

[14] Y. Shirai, N. Adachi, N. Saito, Protein kinase C ε: function in neurons, FEBS J. 275 (2008) 3988 –3994.

[15] R. Srinivasan, D. Wolfe, J. Goss, S. Watkins, W.C. de Groat, A. Sculptoreanu, J.C. Glorioso, Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. Eur. J. Neurosci. 28(2008)1241-1254.

[16] T. Kanno, H. Yamamoto, T. Yaguchi, R. Hi, T. Mukasa, H. Fujikawa, T. Nagata, S. Yamamoto, A. Tanaka, T. Nishizaki, The linoleic acid derivative DCP-LA selectively activates PKC-ε, possibly binding to the phosphatidylserine binding site, J. Lipid Res. 47 (2006) 1146-1156.

[17] J. Hongpaisan, M-K Sun, D.L. Alkon, PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer's disease transgenic mice, J. Neurosci. 31 (2011) 630-643.

[18] V. E. Marquez, P. M. Blumberg, Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C), Acc. Chem. Res. 36 (2003) 434-443.

[19] K. Malolanarashimhan, N. Kedei, D.M. Sigano, J. A. Kelley, C.C Lai, N. E. Lewin, R. J. Surawski, V. A. Pavlyukovets, S. H. Garfield, S. Wincovitch, P. M. Blumberg, V. E. Marquez, Conformationally constrained analogues of diacylglycerol (DAG). 27. Modula-

tion of membrane translocation of protein kinase C (PKC) isozymes γ and δ by diacyl-glycerol lactones (DAG-Lactones) containing rigid-rod acyl groups, J. Med. Chem. 50 (2007) 962-978.

[20]   S. E. Denmark, M. A. Harmata, K. S. White, Studies on the addition of allyl oxides to sulfonylallenes. Preparation of highly substituted allyl vinyl ethers for carbanionic claisen rearrangements, J. Org. Chem. 52 (1987) 4031-4042.

[21]   J. H. Kang, M. L. Peach, Y. Pu, N. E. Lewin, M. C. Nicklaus, P. M. Blumberg, V. E. Marquez, Conformationally constrained analogues of diacylglycerol (DAG). 25. exploration of the sn-1 and sn-2 carbonyl functionality reveals the essential role of the sn-1 carbonyl at the lipid interface in the binding of DAG-lactones to protein kinase C, J. Med. Chem., 48 (2005) 5738-5748.

[22]   A. Tanaka, T. Nishizaki, The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors, Bioorg. Med. Lett. 13 (2003) 1037-1040.

[23]   A. L. K. S. Shun, R. R. Tykwinski, Synthesis of naturally occurring polyynes, Angew. Chem. Int. Ed. 45 (2006) 1034-1057.

[24]   Lewin NE, Blumberg PM, [3H]Phorbol 12,13-dubutyrated binding assay for protein kinase C and related proteins, Methods Molecular Biol. 233 (2003) 129-156.

Table 1. The synthesized DAG-lactones

	Geo	R_1	R_2	Protection	
				PG$_1$	PG$_2$
86	Z	$CH_3(CH_2)_4HC=CHCH_2HC=CH(CH_2)_7$	$CH_2(i\text{-}Pr)$	Bn	PMP
87	E	$CH_3(CH_2)_4HC=CHCH_2HC=CH(CH_2)_7$	$CH_2(i\text{-}Pr)$	Bn	PMP
88	Z	$CH_3(CH_2)_4\overset{CH_2}{CH}-CHCH_2CH-\overset{CH_2}{CH}(CH_2)_7$	$CH_2(i\text{-}Pr)$	Bn	PMP
89	E	$CH_3(CH_2)_4\overset{CH_2}{CH}-CHCH_2CH-\overset{CH_2}{CH}(CH_2)_7$	$CH_2(i\text{-}Pr)$	Bn	PMP
90	Z	$CH_3(CH_2)_4\overset{O}{CH}-CHCH_2CH-\overset{O}{CH}(CH_2)_7$	$CH_2(i\text{-}Pr)$	TBDPS	TBDPS
91	E	$CH_3(CH_2)_4\overset{O}{CH}-CHCH_2CH-\overset{O}{CH}(CH_2)_7$	$CH_2(i\text{-}Pr)$	TBDPS	TBDPS
92	Z	$CH_3(CH_2)_{16}$	$CH_2(i\text{-}Pr)$	PMP	Bn
93	E	$CH_3(CH_2)_{16}$	$CH_2(i\text{-}Pr)$	PMP	Bn
94	Z	$[CH_2(i\text{-}Pr)]_2CHCH_2$	$CH_2(i\text{-}Pr)$	Bn	PMP
95	E	$[CH_2(i\text{-}Pr)]_2CHCH_2$	$CH_2(i\text{-}Pr)$	Bn	PMP
96	Z	$CH_3(CH_2)_7C\equiv C(CH_2)_7$	$CH_2(i\text{-}Pr)$	PMP	Bn
97	E	$CH_3(CH_2)_7C\equiv C(CH_2)_7$	$CH_2(i\text{-}Pr)$	PMP	Bn
98	Z	$CH_3(CH_2)_4C\equiv C-C\equiv C(CH_2)_7$	$CH_2(i\text{-}Pr)$	Bn	PMP
99	E	$CH_3(CH_2)_4C\equiv C-C\equiv C(CH_2)_7$	$CH_2(i\text{-}Pr)$	Bn	PMP
100	Z	$(CH_3)_3C$	$CH_3(CH_2)_4HC=CHCH_2HC=CH(CH_2)_7$	Bn	PMP
101	E	$(CH_3)_3C$	$CH_3(CH_2)_4HC=CHCH_2HC=CH(CH_2)_7$	Bn	PMP
102	Z	$(CH_3)_3C$	$CH_3(CH_2)_4\overset{CH_2}{CH}-CHCH_2CH-\overset{CH_2}{CH}(CH_2)_7$	Bn	PMP
103	E	$(CH_3)_3C$	$CH_3(CH_2)_4\overset{CH_2}{CH}-CHCH_2CH-\overset{CH_2}{CH}(CH_2)_7$	Bn	PMP
104	E	$(CH_3)_3C$	$CH_2CH[CH_2(i\text{-}Pr)]_2$	Bn	PMP
105	Z	$(CH_3)_3C$	$CH_3(CH_2)_{16}$	Bn	PMP
106	E	$(CH_3)_3C$	$CH_3(CH_2)_{16}$	Bn	PMP

Table 2. Binding affinities for PKCα and PKCε in 100% phosphatidylserine (PS).

	Geo	logP	K_i (nM)[a]		Ratio α/ε		Geo	logP	K_i (nM)[a]		Ratio α/ε
			PKCα	PKCε					PKCα	PKCε	
PDBU K_d (nM)			0.28	0.22	1.3	**96**	Z	8.01	12.6	7.12	1.8
86	Z	8.29	7.05	12.2	0.6	**97**	E	8.01	8.7	4.79	1.8
87	E	8.29	4.33	2.14	2.0	**98**	Z	7.82	9.8	13.4	0.7
88	Z	9.19	15.4	9.80	1.6	**99**	E	7.82	8.31	5.24	1.6
89	E	9.19	10.20	5.5	1.9	**100**	Z	8.25	7.20	5.06	1.4
90	Z	5.69	16.5	16.3	1.0	**101**	E	8.25	8.26	4.1	2.0
91	E	5.69	13.2	7.46	1.8	**102**	Z	9.15	33.1	15.2	2.2
92	Z	8.72	43.9	19.3	2.3	**103**	E	9.15	26.7	8.30	3.2
93	E	8.72	30.8	11.4	2.7	**104**	E	5.03	8.3	1.03	8.1
94	Z	5.06	4.74	2.37	2.0	**105**	Z	8.68	31.6	11.5	2.8
95	E	5.06	2.78	1.21	2.3	**106**	E	8.68	24.5	5.9	4.2

[a] Values represent the mean of at least three independent experiments.

Table 3. Binding affinities for PKCα and PKCε at nuclear membrane

	Geo	logP	K_i (nM)[a]		Ratio α/ε		Geo	logP	K_i (nM)[a]		Ratio α/ε
			PKCα	PKCε					PKCα	PKCε	
PDBU K_d (nM)			1.44	0.59	2.44	**96**	Z	8.01	38.7	34.6	1.1
86	Z	8.29	26.2	19.5	1.3	**97**	E	8.01	43.8	9.1	4.8
87	E	8.29	24.7	13.1	1.9	**98**	Z	7.82	44.8	40.3	1.1
88	Z	9.19	44	30.7	1.4	**99**	E	7.82	60.8	12.8	4.8
89	E	9.19	60	19.84	3.0	**100**	Z	8.25	31.1	9.6	3.2
90	Z	5.69	103	63	1.6	**101**	E	8.25	25.7	5.2	4.9
91	E	5.69	116	16.9	6.9	**102**	Z	9.15	73	58.8	1.2
92	Z	8.72	106	34	3.1	**103**	E	9.15	110.3	41	2.7
93	E	8.72	99	47	3.1	**104**	E	5.03	46	1.43	32.2
94	Z	5.06	57	15.6	3.6	**105**	Z	8.68	84.1	45.1	1.9
95	E	5.06	15.4	3.0	5.1	**106**	E	8.68	117	34.2	3.4

[a] Values represent the mean of at least three independent experiments.

Table 4. Affinity ratios of PKCα to PKCε at plasma membrane and nuclear membrane

Z-isomer		K_i ratio PKCα/PKCε		E-isomer		K_i ratio PKCα/PKCε	
		PS	NML			PS	NML
86	*sn*-1	0.6	1.3	**87**	*sn*-1	2.0	1.9
88	*sn*-1	1.6	1.4	**89**	*sn*-1	1.9	3.0
100	*sn*-2	1.4	3.2	**101**	*sn*-2	2.0	4.9
102	*sn*-2	2.2	1.2	**103**	*sn*-2	3.2	2.7
				104	*sn*-2	8.1	32.2
90	*sn*-1	1.0	1.6	**91**	*sn*-1	1.8	6.9
92	*sn*-1	2.3	3.1	**93**	*sn*-1	2.7	2.1
94	*sn*-1	2.0	3.6	**95**	*sn*-1	2.3	5.1
96	*sn*-1	1.8	1.1	**97**	*sn*-1	1.8	4.8
98	*sn*-1	0.7	1.1	**99**	*sn*-1	1.6	4.8
105	*sn*-2	2.8	1.9	**106**	*sn*-2	4.2	3.4

Figure 1. The structure of DAG-lactone

Figure 2. Linoleic acid derivatives: unsaturated, branched, and saturated alkyl chains.

1 R = OH
20 R = H

13

5 R = OH
21 R = H

12

15

2

10

14 R = Cl
16 R = H

11 R = OH
22 R = H

- DAG-lactones with linoleic acid derivatives showed modest selectivity for PKCε.

- DAG-lactones with branched chain showed the best selectivity for PKCε up to 32-fold.

- In nuclear membrane, the selectivity for PKCε versus PKCα was enhanced.